Boston Scientific Corp. (BSX)

28.82
0.02 0.07
NYSE : Health Technology
Prev Close 28.84
Open 29.00
Day Low/High 28.62 / 29.04
52 Wk Low/High 24.54 / 29.93
Volume 5.14M
Avg Volume 7.30M
Exchange NYSE
Shares Outstanding 1.38B
Market Cap 39.85B
EPS 0.10
P/E Ratio 361.12
Div & Yield N.A. (N.A)

Latest News

Boston Scientific Announces Agreement To Acquire NxThera

Boston Scientific Announces Agreement To Acquire NxThera

Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, APU, EBR, FNCB, TROW Downgrades: BSX, HLF, IROQ, KR, KWR, LABL, LLY, NX Initiations: AQN Read on to get TheStreet Quant Ratings' detailed report:

Boston Scientific Announces Acquisition Of EMcision, Limited

Boston Scientific Announces Acquisition Of EMcision, Limited

Acquisition expands endoscopic portfolio to include radiofrequency devices

Boston Scientific Announces Investment And Acquisition Option Agreement With Millipede, Inc.

Boston Scientific Announces Investment And Acquisition Option Agreement With Millipede, Inc.

Millipede, Inc. is developing the IRIS Transcatheter Annuloplasty Ring System to treat severe mitral regurgitation

Quants and Charts Agree That Boston Scientific is a Buy

Quants and Charts Agree That Boston Scientific is a Buy

Boston Scientific shares are poised for more gains

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BSX, CMCM, NWY Downgrades: AMCX, AXP, CPT, IBM, PPL Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Boston Scientific Announces Positive Results From WHISPER Spinal Cord Stimulation Study

Boston Scientific Announces Positive Results From WHISPER Spinal Cord Stimulation Study

Randomized controlled trial demonstrates effectiveness of long-term treatment with sub-perception spinal cord stimulation

Boston Scientific Receives U.S. FDA Approval For Spectra WaveWriter™ Spinal Cord Stimulator System

Boston Scientific Receives U.S. FDA Approval For Spectra WaveWriter™ Spinal Cord Stimulator System

System offers non-opioid treatment option with multiple therapies for people with chronic pain

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

A 'Bomb Cyclone' snowstorm could dump as much as 18 inches on New York and Boston Thursday, the National Weather Service has warned, as the Atlantic coast faces yet another extreme weather battering.

A Medical Device Maker, a Real Estate Giant and Other Stocks That Look Good Short

BSX, SOHU, BPY, IRM and OPNT all recently were downgraded by TheStreet's Quant Ratings.

Boston Scientific Receives U.S. FDA Approval For The Vercise™ Deep Brain Stimulation System

Boston Scientific Receives U.S. FDA Approval For The Vercise™ Deep Brain Stimulation System

Platform Offers Physicians Advanced Technology to Treat Symptoms of Parkinson's disease

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EEI, ENIC, HZO, SSY, UAL, VIRT Downgrades: BSX, BTN, FORK, IRM, SYPR Initiations: COLL, DVMT, GLMD, MVBF Read on to get TheStreet Quant Ratings' detailed report:

Nvidia Is 1 of 30 Well-Known Stocks That Look Ready to Abruptly Change Direction

Nvidia Is 1 of 30 Well-Known Stocks That Look Ready to Abruptly Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns.

Masco, Diplomat Pharmacy, Vail Resorts: 'Mad Money' Lightning Round

Masco, Diplomat Pharmacy, Vail Resorts: 'Mad Money' Lightning Round

Jim Cramer highlights Automatic Data Processing, Masco, Diplomat Pharmacy, Vail Resorts, and Boston Scientific.

What it Takes to Power This Bull: Cramer's 'Mad Money' Recap (Thursday 11/30/17)

What it Takes to Power This Bull: Cramer's 'Mad Money' Recap (Thursday 11/30/17)

Lose the cynicism or you might miss the move. Jim Cramer outlines the reasons for these gains and why investors need to watch them.

Boston Scientific's Jaw-Dropping Stock Dive Is Buying Opportunity: JPMorgan

Boston Scientific's Jaw-Dropping Stock Dive Is Buying Opportunity: JPMorgan

Shares of the worldwide developer, manufacturer, and marketer of medical devices were sent lower on Tuesday after it delayed the commercialization of its Lotus Edge Aortic Valve System.

New Societal Guidelines Recommend Subcutaneous Implantable Cardioverter-Defibrillator For Patients With Ventricular Arrhythmias At Risk Of Sudden Cardiac Death

New Societal Guidelines Recommend Subcutaneous Implantable Cardioverter-Defibrillator For Patients With Ventricular Arrhythmias At Risk Of Sudden Cardiac Death

American Heart Association, American College of Cardiology and Heart Rhythm Society Issue Updated Guidelines Underscoring Benefits of the S-ICD System

Five-year Follow-up Data Demonstrate The WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable To Warfarin Therapy

Five-year Follow-up Data Demonstrate The WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable To Warfarin Therapy

Late-breaking Clinical Trial Data Presented at TCT 2017 with Simultaneous Publication in the Journal of the American College of Cardiology

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Alexion Pharmaceuticals, Bristol-Myers Squibb and Celgene were among the healthcare firms that unveiled quarterly numbers on Oct. 26.

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways

Jim Cramer calls Baxter International, Becton Dickinson, and Boston Scientific the 'Killer Bs'.

Perils of Politics: Cramer's 'Mad Money' Recap (Monday 7/31/17)

Perils of Politics: Cramer's 'Mad Money' Recap (Monday 7/31/17)

Jim Cramer says he wishes Washington would just focus on repatriation and get a win for the U.S. economy and markets.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

Modi's Visit to Meet Trump Focuses Big Spotlight on the H-1B Visa Debate

Modi's Visit to Meet Trump Focuses Big Spotlight on the H-1B Visa Debate

Companies from Amazon to Wipro have a stake in the policies governing tech workers and immigration.

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

From Abbott Labs to Wynn, these names rate checking out.

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

It's a wonder to me how split this market really is.

TheStreet Quant Rating: C (Hold)